Brief: Galectin Therapeutics Inc - As Of March 31, 2021, Had $20.8 Mln Of Cash And Cash Equivalents
17/05/2021 13:35
May 17 (Reuters) - Galectin Therapeutics Inc GALT.O :
* GALECTIN THERAPEUTICS INC - QTRLY LOSS PER SHARE $0.11
* GALECTIN THERAPEUTICS INC - AS OF MARCH 31, 2021, HAD
$20.8
MILLION OF CASH AND CASH EQUIVALENTS
* GALECTIN THERAPEUTICS - SUFFICIENT CASH, TO FUND CURRENTLY
PLANNED OPERATIONS AND RESEARCH AND DEVELOPMENT ACTIVITIES
THROUGH AT LEAST SEPT 30, 2022
Source text for Eikon: [https://bit.ly/3ykR5Pg]
Further company coverage: GALT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Galectin Therapeutics
See all newsGalectin Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Galectin Therapeutics Reports June 30, 2026 Financial Results
Galectin Therapeutics Q2 loss widens
Galectin Therapeutics Inc expected to post a loss of 9 cents a share - Earnings Preview
Galectin Therapeutics rises as FDA clears path for late-stage liver drug study